# Additional Expert Peer Review Report

**Context:** These experts have reviewed the manuscript and the previous feedback from the Statistician, Health Economist, and Data Scientist.

---

## Reviewer 4: Professor of Bioethics & Political Philosophy
*Focus: Normative frameworks, equity weights, transparency of value judgments.*

### Critique
1.  **Implicit Value Judgments**: "The manuscript treats 'equity weights' and the 'Atkinson index' as technical parameters. They are not. They represent profound moral choices about how much we value the health of the worst-off. The manuscript must explicitly state the *ethical framework* being operationalized (e.g., prioritarianism vs. egalitarianism)."
2.  **The "Black Box" of Fairness**: "If a decision-maker uses your tool to prioritize a policy because it reduces inequality, they need to know *which* definition of inequality is being used. Is it pure health inequality (Gini) or inequality aversion (Atkinson)? The software documentation must explain these normative choices to the user, not just the math."
3.  **Supplements vs. Manuscript**: "The detailed philosophical justification for specific equity weights (e.g., why $\epsilon=1.5$?) belongs in the **Supplement**. However, the **Manuscript** must contain a 'Normative Framework' section acknowledging that DCEA is an ethical enterprise, not just a statistical one."

### Recommendations
*   **Manuscript**: Add a subsection in the Introduction or Methods titled "Normative Framework", citing relevant literature (e.g., Cookson, Parfit).
*   **Software**: Ensure the CLI or reports output a "Normative Assumptions" summary (e.g., "This analysis assumes an inequality aversion of 1.5...").
*   **Supplements**: Include a "Guide to Equity Weights" explaining the implications of different parameter choices for non-philosophers.

---

## Reviewer 5: Senior Health Policy Analyst
*Focus: Decision relevance, interpretability, real-world utility.*

### Critique
1.  **The "So What?" Problem**: "The 'Value of Perspective' (VoP) sounds academically interesting, but how do I use it? If the VoP is \$5 million, does that mean I should delay the decision? Or does it mean I should fund a societal perspective study? The manuscript needs to translate the metric into a **decision rule**."
2.  **Policy Briefs**: "I see a `policy_brief.md` in the file list, but the manuscript doesn't describe it. For me, the *automated generation of policy briefs* is the killer feature. Most decision-makers will never look at the Python code. Highlight this! Show an example of the generated brief."
3.  **Budget Impact**: "You mention Budget Impact Analysis (BIA). In the real world, BIA often trumps CEA. If your tool does BIA, it needs to be prominent. Don't bury it."

### Recommendations
*   **Manuscript**: Add a "Case Study: Policy Interpretation" section. Walk through a specific result: "The VoP was \$X, suggesting that collecting societal data is cost-effective..."
*   **Manuscript**: Showcase the `policy_brief.md` output as a figure.
*   **Approach**: Ensure the BIA results are presented alongside the CEA/DCEA results in the main dashboard.

---

## Reviewer 6: Expert in Uncertainty Quantification (UQ)
*Focus: Mathematical rigor, simulation stability, variance decomposition.*

### Critique
1.  **VoP Formulation**: "I agree with the Health Economist: we need the equations. But specifically, I need to see how you handle the **nested uncertainty**. VoP implies calculating the Expected Value of Information (EVI) on the *perspective* parameter. Is this a nested Monte Carlo loop? If so, the computational burden is massive. How do you handle convergence? If you are using a proxy or approximation, you must prove its validity."
2.  **Sobol Indices Stability**: "You are using Sobol indices for global sensitivity analysis. These require large sample sizes ($N > 1000(k+2)$) to stabilize. The manuscript must report the sample size used and the confidence intervals of the indices. Without this, the sensitivity analysis is anecdotal."
3.  **Correlation Structures**: "In health economics, parameters are highly correlated (e.g., costs of treatment A and B). If your PSA assumes independence (which standard probabilistic sampling often does unless specified), your VoP estimates will be wrong. You must describe how you handle parameter correlation (e.g., Cholesky decomposition, copulas)."

### Recommendations
*   **Manuscript**: The "Methodology" section must explicitly define the VoP estimator and the Monte Carlo integration scheme.
*   **Supplements**: Provide a "Convergence Diagnostics" report showing that the number of simulations was sufficient for stable VoP estimates.
*   **Software**: Add a check for parameter correlation in the input `parameters.yaml`.

---

## Consolidated Advice for the Author

### 1. The "Methodology" Section is Critical
You need a rigorous mathematical section that satisfies the **Health Economist** and **UQ Expert**.
*   Define DCEA (Equity-weighted Net Benefit).
*   Define VoP (Difference in Expected Net Benefit between perspectives, weighted by decision discordance probability).
*   Describe the Monte Carlo algorithm and convergence checks.

### 2. The "Normative" Dimension
Satisfy the **Ethicist**:
*   Acknowledge the ethical choices in the text.
*   Add a "Normative Assumptions" output to the software reports.

### 3. The "Practical" Dimension
Satisfy the **Policy Analyst** and **Software Engineer**:
*   Show the code (API).
*   Show the output (Policy Brief, Dashboard).
*   Explain how to interpret the VoP for a real decision.

### 4. Structure of the Submission
*   **Main Manuscript (~20 pages)**:
    *   Intro (Technical + Normative context).
    *   Methodology (Math + UQ).
    *   Software Architecture (Design + API).
    *   Case Study (Results + Policy Interpretation).
    *   Discussion (Limitations + Future Work).
*   **Supplement A**: Mathematical Proofs & Convergence Diagnostics.
*   **Supplement B**: Guide to Equity Weights (Ethical Framework).
*   **Supplement C**: Full "parameters.yaml" and Data Dictionary.
